Citicholine

Citicholine is broken down in the small intestine into cytidine and choline after ingestion. These two components are absorbed separately and re-synthesize as citicoline in cells. In the brain, cytidine is converted to uridine, and together with choline supports synthesis of phosphatidylcholine and other membrane phospholipids. Choline also supports acetylcholine production. By providing precursors for both phospholipid synthesis and the cholinergic system, citicholine supports brain function on multiple levels. It crosses the blood-brain barrier effectively, distinguishing it from basic choline forms that are limited to peripheral and hepatic functions. Clinical evidence supports citicholine for age-related cognitive decline, stroke recovery (with mixed results in large trials), and possibly cognitive support in healthy adults. The branded form Cognizin (Kyowa Hakko) is the most-studied version and has FDA GRAS status for food use.

Typical doses range from 250 to 2,000 mg per day. Most studies in healthy adults use 250 to 500 mg per day. Clinical trials in stroke and TBI have used 500 to 2,000 mg per day. Effects on cognition typically develop over 4 to 12 weeks.

WHEN: Take citicholine in the morning or early afternoon, as some users find it mildly stimulating. Pre-task or pre-workout use may support focus. HOW: Take with water; food not required. Split larger daily doses into two administrations. Allow 4 to 12 weeks of consistent use to evaluate effects.

Citicholine is generally very well tolerated. Mild side effects include headache, insomnia, and GI upset, all uncommon. There is no established Tolerable Upper Intake Level. Long-term safety in research extends to several months with no major concerns.

Citicholine may interact with cholinesterase inhibitors used in Alzheimer's, providing additional acetylcholine precursor. Levodopa effects may be modestly enhanced. Otherwise, few significant drug interactions are documented.